<DOC>
	<DOCNO>NCT02684565</DOCNO>
	<brief_summary>Branching chain amino acid ( BCAA ) beneficial detrimental effect metabolism establish therefore warrant investigation . In preliminary study , investigator find BCAAs enhance glucose metabolism lean mouse promote glucose intolerance obese mouse . In lean mouse , BCAAs decrease adiposity enhance glucose utilization insulin sensitivity different tissue . But obese mouse , BCAAs ' effect mediate impaired insulin signal fat tissue . This study examine 10 obese subject pre-diabetes examine effect take BCAA supplement monitor subject blood glucose , insulin , triglyceride level oral glucose tolerance test repeat occasion see change note glucose regulation .</brief_summary>
	<brief_title>Effects Branch Chain Amino Acids Glucose Tolerance Obese Pre-Diabetic Subjects</brief_title>
	<detailed_description>Branched-Chain Amino Acids ( BCAAs , include leucine , isoleucine , valine ) regulate multiple cellular function nutrient signal . For example , BCAAs regulate insulin glucagon secretion thus glucose metabolism1 . BCAAs , especially leucine , one key regulator mTOR signaling , central component complex signal network insulin signaling , cell growth , proliferation . BCAAs also regulate protein synthesis degradation various tissue . Increasing dietary uptake BCAAs improve parameter associate obesity T2DM , body composition glycemia level . However , beneficial effect conclusive . Moreover , study show circulate branched-chain amino acid concentration associate obesity future insulin resistance child adolescent . This 12-week , randomize , crossover study 10 obese subject prediabetes . Subjects randomly assign take 20g BCAA low-BCAA protein day 4 week , switch BCAA low-BCAA protein 4 week 2-week washout . At baseline week 4 , 6 10 week glucose , insulin triglyceride level test time 0 , 30 min , 60 min , 120 min 75 gram glucose load . In addition laboratory test vital sign , weight body composition do .</detailed_description>
	<mesh_term>Prediabetic State</mesh_term>
	<criteria>1 . Age 2050 year age screen 2 . BMI 27 35 3 . Fasting glucose level &gt; 100 , &lt; 126 mg/dL HgbA1c &gt; 5.7 % &lt; 6.4 % 4 . Waist circumference &gt; 40 cm men &gt; 35 woman 5 . Subjects must read sign Institutional Review Boardapproved write informed consent prior initiation study specific procedure enrollment . A subject exclude condition might compromise ability give truly informed consent . 1 . Any subject history diabetes mellitus medication , serious medical condition , chronic hepatic renal disease , bleed disorder , congestive heart disease , cancer ( except skin basal cell carcinoma ) chronic diarrhea disorder , myocardial infarction , coronary artery bypass graft , angioplasty within 6 month prior screen , current diagnosis uncontrolled hypertension ( define systolic BP &gt; 160mmHg , diastolic BP &gt; 95mmHg ) , active chronic gastrointestinal disorder , bulimia , anorexia , endocrine disease ( except thyroid disease require medication ) indicate medical history routine physical examination . 2 . Any subject screening laboratory value outside laboratory normal range consider clinically significant study participation investigator . 3 . Any subject currently use tobacco product . 4 . Any history gastrointestinal disease except appendectomy . 5 . Any antibiotic laxative use 2 month study . 6 . Any subject unable unwilling comply study protocol . 7 . Any subject allergic soy product .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>pre-diabetes</keyword>
	<keyword>blood glucose regulation</keyword>
	<keyword>branch chain amino acid</keyword>
	<keyword>diabetes</keyword>
	<keyword>low blood sugar</keyword>
</DOC>